## **REMARKS**

Applicants thank the Examiner for the allowance of claims 1-13. In an effort to expedite prosecution, Applicants cancelled Claim 25 and 28-33 and amended Claim 15 to specifically state the condition to be prevented and/or treated. Claim 26 was amended to reflect proper dependence. Applicants reserve the right to file a divisional or continuation application directed to any unclaimed subject matter therein. Applicants believe this renders moot the Examiner's 35 U.S.C. § 112 (1<sup>st</sup> Par.) rejection. Accordingy, Applicants have not provided herein any remarks rebutting the rejection.

At this time, Applicants respectfully request that the Examiner rejoin Claims 15-27 for consideration of allowance. The withdrawn claims depend from the allowed product claims and are commensurate in scope with the allowed product claims.

## **CONCLUSION**

Applicants respectfully request entry of the amendments herein above, and an early and favorable allowance.

Respectfully submitted,

Date: August 29, 2007

Pfizer Inc.
Patent Department, MS 8260-1611

Eastern Point Road Groton, Connecticut 06340

(860) 715-4288

/ Martha G. Munchhof /
Martha G. Munchhof
Attorney for Applicant(s)

Reg. No. 47,811